The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs

The European Society for Medical Oncology (ESMO) Congress always showcases practice-changing data across a spectrum of diseases, and this year, there is much to expect in gynecologic oncology. At the forefront are 2 late-breaking phase 3 endometrial cancer trials in a Presidential Symposium, new overall survival (OS) data from a frontline immunotherapy trial, and several antibody-drug conjugate (ADC) updates in platinum-resistant ovarian cancer (PROC). Here are 5 abstracts that anyone involved in the care of patients with gynecologic malignancies should be paying attention to.